title: Effect of diquafosol ophthalmic solution on the optical quality of the eyes in patients with aqueous-deficient dry eye.
abstract: OBJECTIVE
  To investigate the short- and long-term effects of diquafosol ophthalmic solution on the optical quality of the eyes in patients with aqueous-deficient dry eye.
  
  
  METHODS
  Sixteen eyes in 16 patients with mild or moderate aqueous-deficient dry eye were treated with 3% diquafosol ophthalmic solution. Ocular higher-order aberrations (HOAs) were measured with a wavefront sensor before and at 15 min after diquafosol instillation at the baseline visit and at 4 weeks after treatment initiation. Dry eye symptoms, tear break-up time (BUT), corneal/conjunctival fluorescein staining and Schirmer's test were also evaluated before and after treatment with diquafosol.
  
  
  RESULTS
  Treatment with diquafosol ophthalmic solution significantly improved dry eye symptoms, corneal staining and BUT. Compared with mean total HOAs at baseline (0.180 ± 0.06 μm), those at 4 weeks after treatment significantly decreased (0.148 ± 0.039 μm; p = 0.035), whereas those 15 min after diquafosol instillation at the baseline visit did not change significantly (0.170 ± 0.049 μm; p = 0.279).
  
  
  CONCLUSIONS
  Although no significant change in HOAs was observed as a short-term effect of a single-drop instillation of diquafosol, long-term use of diquafosol to treat aqueous-deficient dry eye reduced HOAs as well as improved corneal epithelial damage and tear film stability.
authors.affiliation: Department of Ophthalmology, Osaka University Graduate School of Medicine, Osaka, Japan.
authors.forename: Shizuka
authors.initials: S
authors.lastname: Koh
authors.forename: Naoyuki
authors.initials: N
authors.lastname: Maeda
authors.forename: Chikako
authors.initials: C
authors.lastname: Ikeda
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Oie
authors.forename: Takeshi
authors.initials: T
authors.lastname: Soma
authors.forename: Motokazu
authors.initials: M
authors.lastname: Tsujikawa
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Watanabe
authors.forename: Kohji
authors.initials: K
authors.lastname: Nishida
mesh_terms: D000287:Administration, Topical; D000368:Aged; D001082:Aqueous Humor / Q000378:metabolism*; D057108:Corneal Wavefront Aberration / Q000503:physiopathology*; D005260:Female; D006801:Humans; D007638:Keratoconjunctivitis Sicca / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D011122:Polyphosphates / Q000627:therapeutic use*; D058912:Purinergic P2Y Receptor Agonists / Q000627:therapeutic use*; D012859:Sjogren's Syndrome / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D011795:Surveys and Questionnaires; D013666:Tears / Q000737:chemistry; D014500:Uracil Nucleotides / Q000627:therapeutic use*
chemical_list: D009883:Ophthalmic Solutions; D011122:Polyphosphates; D058912:Purinergic P2Y Receptor Agonists; D014500:Uracil Nucleotides; C403315:diquafosol
keywords: diquafosol ophthalmic solution; dry eye; higher-order aberrations; tear film